title: Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention.
abstract: OBJECTIVE
  Provide a critical summary of the latest interpretation of findings from the Prostate Cancer Prevention Trial (PCPT).
  
  
  METHODS
  Findings from PCPT and recently published post-hoc analyses are reviewed.
  
  
  RESULTS
  PCPT demonstrated that finasteride can reduce the prevalence of prostate cancer, permitted the first large-scale assessment of the performance characteristics of prostate-specific antigen for prostate cancer screening, and identified new-onset erectile dysfunction as an early predictor of cardiovascular events.
  
  
  CONCLUSIONS
  PCPT has and will continue to yield valuable information regarding future strategies for prostate cancer prevention and detection, benign prostatic hyperplasia, and other matters of public health importance.
authors.affiliation: Department of Urology, University of Texas Health Science Center at San Antonio, TX 78229, USA. canbyhagino@uthscsa.edu
authors.forename: Edith
authors.initials: E
authors.lastname: Canby-Hagino
authors.forename: Javier
authors.initials: J
authors.lastname: Hernandez
authors.forename: Timothy C
authors.initials: TC
authors.lastname: Brand
authors.forename: Ian
authors.initials: I
authors.lastname: Thompson
mesh_terms: D058891:5-alpha Reductase Inhibitors; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000517:prevention & control*; D012307:Risk Factors
chemical_list: D058891:5-alpha Reductase Inhibitors; D004791:Enzyme Inhibitors; D018120:Finasteride; D017430:Prostate-Specific Antigen